YU40002A - Antipikornavirusna jedinjenja i kompozicije, njihove farmaceutske upotrebe, i materijali za njihove sinteze - Google Patents

Antipikornavirusna jedinjenja i kompozicije, njihove farmaceutske upotrebe, i materijali za njihove sinteze

Info

Publication number
YU40002A
YU40002A YU40002A YUP40002A YU40002A YU 40002 A YU40002 A YU 40002A YU 40002 A YU40002 A YU 40002A YU P40002 A YUP40002 A YU P40002A YU 40002 A YU40002 A YU 40002A
Authority
YU
Yugoslavia
Prior art keywords
compounds
synthesis
compositions
formula
materials
Prior art date
Application number
YU40002A
Other languages
English (en)
Inventor
Peter S. Dragovich
Thomas J. Prins
Ru Zhou
Theodore O. Johnson
Original Assignee
Agouron Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharmaceuticals Inc. filed Critical Agouron Pharmaceuticals Inc.
Publication of YU40002A publication Critical patent/YU40002A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Jedinjenja formule: u kojoj su promenljive vrednosti formule kao što je prethodno definisano, otkriveno je da poboljšano inhibiraju ili blokiraju biološku aktivnost pikornavirusne 3C proteaze. Takodje su otkrivena jedinjenja formule: u kojoj su promenljive vrednosti formule kao što je prethodno definisano, a koje poboljšano inhibiraju ili blokiraju biološku aktivnost pikornavirusne 3C proteaze. Ova jedinjenja, kao i farmaceutske smese koje sadrže ova jedinjenja, korisna su za lečenje pacijenata ili domaćina zaraženih sa jednim ili više pikornavirusa, kao što su rinovirus 3C proteaze. Intermedijari i sintetički postupci za dobijanje takvih jedinjenja takodje su opisani.[Compounds of formula (I), where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the picornaviral 3C protease. Also disclosed are compounds of formula (II) where the formula variables are as defined herein that advantageously inhibit or block the biological activity of the picornaviral 3C protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with one or more picornaviruses, such as rhinovirus 3C proteases. Intermediates and synthetic methods for preparing such compounds are also described.
YU40002A 1999-12-03 2000-12-01 Antipikornavirusna jedinjenja i kompozicije, njihove farmaceutske upotrebe, i materijali za njihove sinteze YU40002A (sh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16898699P 1999-12-03 1999-12-03
US19205200P 2000-03-24 2000-03-24

Publications (1)

Publication Number Publication Date
YU40002A true YU40002A (sh) 2006-01-16

Family

ID=26864652

Family Applications (1)

Application Number Title Priority Date Filing Date
YU40002A YU40002A (sh) 1999-12-03 2000-12-01 Antipikornavirusna jedinjenja i kompozicije, njihove farmaceutske upotrebe, i materijali za njihove sinteze

Country Status (31)

Country Link
US (1) US6514997B2 (sh)
EP (1) EP1252145A1 (sh)
JP (1) JP2003515591A (sh)
KR (1) KR20020058076A (sh)
CN (1) CN1402710A (sh)
AP (1) AP2002002510A0 (sh)
AR (1) AR030540A1 (sh)
AU (1) AU777943B2 (sh)
BG (1) BG106754A (sh)
BR (1) BR0016742A (sh)
CA (1) CA2392504A1 (sh)
CO (1) CO5261566A1 (sh)
CZ (1) CZ20021906A3 (sh)
DO (1) DOP2000000108A (sh)
EA (1) EA200200625A1 (sh)
EE (1) EE200200281A (sh)
HK (1) HK1052933A1 (sh)
HU (1) HUP0204006A3 (sh)
IL (1) IL149427A0 (sh)
IS (1) IS6378A (sh)
MX (1) MXPA02005124A (sh)
NO (1) NO20022589L (sh)
NZ (1) NZ518934A (sh)
OA (1) OA12101A (sh)
PA (1) PA8507801A1 (sh)
PE (1) PE20020157A1 (sh)
PL (1) PL356062A1 (sh)
SK (1) SK7602002A3 (sh)
UY (1) UY26465A1 (sh)
WO (1) WO2001040189A1 (sh)
YU (1) YU40002A (sh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1198838C (zh) 1998-04-30 2005-04-27 阿格罗尼制药公司 抗小rna病毒化合物及其制备方法和用途
PE20011277A1 (es) 2000-04-14 2002-01-07 Agouron Pharma Compuestos y composiciones antipicornavirales, sus usos farmaceuticos y los materiales para su sintesis
PL365470A1 (en) * 2000-06-14 2005-01-10 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
ATE438624T1 (de) * 2000-12-28 2009-08-15 Shionogi & Co 2-pyridonderivate mit affinität für den cannabinoid-typ-2-rezeptor
WO2004002405A2 (en) * 2002-06-26 2004-01-08 Bristol-Myers Squibb Company Amino-bicyclic pyrazinones and pyridinones
EP1606019A1 (en) * 2003-03-07 2005-12-21 The University Court of The University of Aberdeen Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders
WO2004093860A1 (en) * 2003-04-21 2004-11-04 Pfizer Inc. Inhibitors of sars related coronavirus proteinase
US20040235952A1 (en) * 2003-05-05 2004-11-25 Agouron Pharmaceuticals, Inc. Inhibitors of severe acute respiratory syndrome (SARS) 3C-like proteinase
CA2550515A1 (en) * 2003-12-31 2005-07-21 Taigen Biotechnology Protease inhibitors
US7462594B2 (en) * 2003-12-31 2008-12-09 Taigen Biotechnology Co., Ltd. Peptide-like compounds that inhibit coronaviral 3CL and flaviviridae viral proteases
WO2005110988A1 (en) * 2004-05-07 2005-11-24 Janssen Pharmaceutica, N.V. Pyridone compounds as inhibitors of bacterial type iii protein secretion systems
GB0702862D0 (en) * 2007-02-14 2007-03-28 Univ Aberdeen Therapeutic compounds
KR100891699B1 (ko) 2007-04-10 2009-04-03 광주과학기술원 7-아미노-4-((ｓ)-3-(4-플루오로페닐)-2-((r)-3-메틸-2-(5-메틸이소옥사졸-3-카복사미도)부탄아미도)프로판아미도)-7-옥소-2-헵테노에이트 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 바이러스성 질환의 예방 및 치료용 약학적 조성물
JP5734853B2 (ja) * 2008-08-29 2015-06-17 トレヴェンティス コーポレイションＴｒｅｖｅｎｔｉｓ Ｃｏｒｐｏｒａｔｉｏｎ 神経系疾患用の診断ツール及び治療としてのブチリルコリンエステラーゼリガンド
KR101385855B1 (ko) * 2012-10-16 2014-04-22 이동익 카뎁신 검출용 다이아로마틱 아미노산 기질
CA3024120A1 (en) * 2016-05-13 2017-11-16 Emory University Peptidomimetics for the treatment of norovirus infection
US11124497B1 (en) 2020-04-17 2021-09-21 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
US11174231B1 (en) 2020-06-09 2021-11-16 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652676A (en) 1985-05-06 1987-03-24 General Foods Corporation L-aminodicarboxylic acid alkenes
US5374623A (en) 1992-08-20 1994-12-20 Prototek, Inc. Cysteine protease inhibitors effective for in vivo use
US5514778A (en) 1993-07-01 1996-05-07 Eli Lilly And Company Anti-picornaviral agents
US5486623A (en) 1993-12-08 1996-01-23 Prototek, Inc. Cysteine protease inhibitors containing heterocyclic leaving groups
IL112759A0 (en) 1994-02-25 1995-05-26 Khepri Pharmaceuticals Inc Novel cysteine protease inhibitors
IT1269511B (it) 1994-05-17 1997-04-01 Univ Degli Studi Milano Derivati di acidi ammino-solfonici , loro impiego nella sintesi di pseudopeptidi e procedimento per la loro preparazione
US5498616A (en) 1994-11-04 1996-03-12 Cephalon, Inc. Cysteine protease and serine protease inhibitors
WO1996030395A2 (en) 1995-03-31 1996-10-03 Takeda Chemical Industries, Ltd. Cysteine protease inhibitor
IT1281031B1 (it) 1995-11-17 1998-02-11 Carlo Chiaves Struttura prefabbricata per la realizzazione di opere costruite a cielo aperto, particolarmente per cavalcavia autostradali,
AU722704B2 (en) 1996-05-14 2000-08-10 Agouron Pharmaceuticals, Inc. Inhibitors of picornavirus 3c proteases and methods for their use and preparation
US5856530A (en) 1996-05-14 1999-01-05 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and methods for their use and preparation
WO1997049668A1 (en) 1996-06-13 1997-12-31 Smithkline Beecham Corporation Inhibitiors of cysteine protease
CA2289541A1 (en) 1997-03-28 1998-10-08 Peter S. Dragovich Antipicornaviral compouds, compositions containing them, and methods for their use
US6020371A (en) 1997-03-28 2000-02-01 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds compositions containing them and methods for their use
US6331554B1 (en) 1997-03-28 2001-12-18 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds, compositions containing them, and methods for their use
US5962487A (en) 1997-12-16 1999-10-05 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and methods for their use and preparation
CN1198838C (zh) 1998-04-30 2005-04-27 阿格罗尼制药公司 抗小rna病毒化合物及其制备方法和用途
US6369226B1 (en) 1999-06-21 2002-04-09 Agouron Pharmaceuticals, Inc. Substituted benzamide inhibitors of rhinovirus 3C protease
ES2230135T3 (es) 1999-08-04 2005-05-01 Agouron Pharmaceuticals, Inc. Compuestos y composiciones anti-picornavirales; utilizaciones farmaceuticas y materiales utilizados para su sintesis.
IL147862A0 (en) 1999-08-24 2002-08-14 Agouron Pharma Process and intermediates for the preparation os isoxazolecaroxamides and analogues
PE20010517A1 (es) 1999-08-24 2001-05-16 Agouron Pharma Las rutas sinteticas eficientes para la preparacion de los inhibidores de la proteasa del rinovirus y los intermedios claves

Also Published As

Publication number Publication date
IL149427A0 (en) 2002-11-10
DOP2000000108A (es) 2003-03-15
JP2003515591A (ja) 2003-05-07
NZ518934A (en) 2003-11-28
IS6378A (is) 2002-05-10
KR20020058076A (ko) 2002-07-12
HUP0204006A2 (hu) 2003-03-28
EA200200625A1 (ru) 2002-12-26
US6514997B2 (en) 2003-02-04
WO2001040189A1 (en) 2001-06-07
UY26465A1 (es) 2001-06-29
AU1809401A (en) 2001-06-12
CA2392504A1 (en) 2001-06-07
BR0016742A (pt) 2002-09-03
NO20022589D0 (no) 2002-05-31
BG106754A (bg) 2003-07-31
EE200200281A (et) 2003-06-16
PL356062A1 (en) 2004-06-14
CZ20021906A3 (cs) 2003-02-12
CN1402710A (zh) 2003-03-12
US20010047006A1 (en) 2001-11-29
HUP0204006A3 (en) 2004-11-29
AU777943B2 (en) 2004-11-04
EP1252145A1 (en) 2002-10-30
MXPA02005124A (es) 2003-01-28
HK1052933A1 (zh) 2003-10-03
NO20022589L (no) 2002-07-31
AP2002002510A0 (en) 2002-06-30
SK7602002A3 (en) 2003-02-04
OA12101A (en) 2006-05-04
PE20020157A1 (es) 2002-02-22
CO5261566A1 (es) 2003-03-31
PA8507801A1 (es) 2002-08-26
AR030540A1 (es) 2003-08-27

Similar Documents

Publication Publication Date Title
AP2003002915A0 (en) HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis.
PL354030A1 (en) Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
YU40002A (sh) Antipikornavirusna jedinjenja i kompozicije, njihove farmaceutske upotrebe, i materijali za njihove sinteze
YU66000A (sh) Antipikovirusna jedinjenja, njihovo dobijanje i upotreba
PL371414A1 (en) Disubstituted thiazolyl carboxanilides and their use as microbicides
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
DE60112330D1 (en) Pyrazolopyridinderivate
SE9804212D0 (sv) Compounds
WO2001079167A3 (en) Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
DK0975588T3 (da) Antipicornavirale forbindelser, sammensætninger indeholdende dem og fremgangsmåder til deres anvendelse
ATE432936T1 (de) Imidazotriazin verbindungen zur behandlung von krebserkrankungen
DE60227421D1 (de) Rmazeutische zusammensetzung und verwendung davon
WO2001014576A3 (en) Process and intermediates for the preparation of isoxazolecaroxamides and analogues
WO2001096297A3 (en) Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
MXPA02002007A (es) Compuestos de bencimidazol sustituidos con alcoxi, preparaciones farmaceuticas que contienen los mismos, metodos para usarlos.
EP1329457A3 (en) Antipicornaviral compounds, their preparation and use
WO2002023784A3 (en) Cysteine protease inhibitors
IL140919A0 (en) N-substituted azabicycloheptane derivatives, production and use thereof